Refine by
Immunotherapy Articles & Analysis
391 news found
In the meantime, targeted therapies target individual molecules or genes, sparing healthy tissues from collateral damage. The immunotherapy APIs energize the immune system to target cancer cells; hormone therapies target hormone-related cancers by blocking hormones that promote tumour growth. ...
During the event, the team demonstrated their pipeline from phage construction to screening and their masterpiece in discovering PTM specific antibodies, anti-idiotype antibodies, which gives researchers an edge when looking to discover novel targets in immunotherapy, cancer, and infectious diseases. Another hot topic during the festival was the growing interest in single domain ...
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...
ByOncoVITA
Then we screen out characteristic neoantigens encoded, hoping to make a huge contribution to tumor immunotherapy.” Scientists of Alfa Cytology work on tailored projects by diagnosing PC and identifying its biomarkers. ...
And with its ability to adapt to industry advancements and deliver customized solutions, Alfa Chemistry continues to lead the way in pushing the boundaries of vaccine science and ...
This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. CD Genomics' latest enhancements in TCR-Seq technology promise to provide even more accurate and comprehensive insights into the adaptive immune system. ...
The company has also rebranded its name from eTheRNA immunotherapies to etherna , and has launched new websites. etherna (“the Company”), a leading mRNA/LNP technologies company, announced today that Bernard Sagaert has been confirmed-as Chief Executive Officer. ...
ByeTheRNA
Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. ...
However, recent studies have shown that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for EBV-associated cancer immunotherapy. These new reagents can be used to study herpesviruses in the laboratory and to develop assays to detect and measure herpesvirus infection. ...
“Our innovative drug delivery solutions are ideal for a wide range of pharmaceutical and biotech applications, such as gene therapy, immunotherapy, hormonal therapy, anti-infectives, and vaccines,” said the Marketing Chief of CD Formulation. ...
Along with these traditional treatments, more research is also being conducted into immunotherapy and gene therapy techniques that hold great promise in providing new treatments for cancer. ...
These data were published in an abstract by the Society for Immunotherapy of Cancer (SITC) and will be presented in a poster presentation today at the 37th Annual SITC Meeting in Boston, MA. ...
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announces entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine ...
Targeting these tumors with novel cellular immunotherapies will help address the unmet need for new treatment options for ovarian cancer patients. ...
Fabentech will benefit from a grant of 5 million euros in this respect. A polyclonal immunotherapy technological platform dedicated to health emergency situations Fabentech’s primary asset lies in its innovative technological platform for producing polyclonal antibodies, Fabshield®. ...
(NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. ...
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE’s new approach has no known competitors and is covered by a comprehensive patent portfolio. ...
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary tumor ablation technology utilizing UNO results in a potent innate and adaptive immune response that prevents metastases and resulted ...